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INTRODUCTION
The defining tumors in NF1 are discrete and plexiform neurofibromas and malignant peripheral nerve sheath tumors (MPNST). Much of the morbidity and mortality in NF1 patients is caused by these peripheral nerve tumors.
Improvement of existing therapies and development of new therapies for these tumors is hindered by difficulties to systematically characterize tumor development and to control treatment strategies, and by the lack of appropriate animal models. The goal of the work funded by this grant is to develop appropriate animal models for the testing of experimental therapies for MPNST. Oncolytic viruses will be used to explore their efficacy in MPNST therapy in these models.
Genetic and cell biological technologies have recently made available a number of mouse models in which peripheral nerve tumors and MPNSTs are formed. In this proposal we will use these and develop other models to determine the therapeutic efficacy of oncolytic herpes simplex type I viruses (HSV) alone and in combination with anti-tumor immune-and antiangiogenesis treatment, respectively. Oncolytic HSV vectors have been shown to be effective treatments for a number of nervous system tumors in animal models, such as glioblastoma and medulloblastoma (Mineta, Rabkin et al. 1995; Mashour, Moulding et al. 2001) . These viruses have also been shown to be safe for use in humans in a phase 1 clinical trial (Markert, Medlock et al. 2000) .
Taken together, we will establish whether oncolytic HSV vectors are effective against MPNST in animal models, whether anti-tumor immunity can be induced against these tumors, and whether expression of anti-angiogenic factors from oncolytic HSV vectors provides additional benefit. As stated in the last annual report, instead of generating defective HSV vectors expressing anti-angiogenic factors, we have generated recombinant oncolytic HSV vectors, which are much easier to produce and are potentially translatable to the clinic. We have completed this Task. 3. Therapy by local delivery of oncolytic virus (Task 5).
Murine cell model (nude mice).
In the first annual report, we described studies examining the inhibition of subcutaneous MPNST M1 and M4 tumors by G47A. Here we demonstrate the significant inhibition of subcutaneous MPNST M2 tumors by bG47A-empty (Fig 3) .
Murine cell model (syngeneic, immune competent)
We are currently testing the growth of the Nfl/Trp53 knockout MPNST tumor cell lines in C57B1/6 x 129sv F1 mice (cell lines were derived from transgenic mice maintained on a mixed C57B1/6 x 129sv background (Vogel, Klesse et al. 1999) ) in order to generate an immunecompetent MPNST model. If we are successful, we will be able to examine systemic delivery of oncolytic HSV (Task 6).
Anti-angiogenesis targqetingq of MPNST (Task 7).

In vitro activities of oncolytic HSV expressing dnFGFR or PF4.
We have devoted considerable effort to developing anti-angiogenesis therapy in the context of oncolytic HSV for MPNST, for many of the reasons outlined in the proposal (ie., neurofibromas and MPNSTs are highly angiogenic and neurofibromas overexpress many angiogenic factors (Kurtz and Martuza 2002) ), and made substantial progress. In the last annual report, we described the generation of a set of oncolytic HSV vectors expressing antiangiogenic factors; bG47A-dnFGFR (G47A expressing dominant-negative FGFR), bG47A-PF4
(G47A expressing platelet factor 4), and the control bG47A-empty (G47A with no transgene).
These vectors replicate similarly in mouse MPNST Nfl-/p53-cell lines (Ml and M2) and proliferating HUVECs (Fig 1) . This demonstrates that expression of the transgene did not alter HUVEC M1 MZ virus replication in these cells and their oncolytic activity should be the same. Any differences in efficacy should therefore be due to the direct effect of the expressed transgene on target cells. This is illustrated in Fig. 2 , where we have compared the in vitro cytotoxicity of the vectors on a number of cell lines. The effect of both dnFGFR and PF4 is greatest in HUVECs, where the EC50 was <20% that seen with bG47A-empty. Interestingly, the MPNST cells (Ml and M2) are quite sensitive to dnFGFR expression (Fig. 2 upper) and only minimally sensitive to PF4 (Fig. 2 lower). This suggests that in immune-deficient mice bearing M1 tumors, bG47A-dnFGFR should have three activities; oncolytic, anti-angiogenic, and anti-tumor. 
In vivo activities of oncolytic HSV expressing dnFGFR or PF4.
We established subcutaneous M2 tumors, in athymic mice, which were then treated with intratumoral injections of PBS or 107 pfu of bG47A-empty, bG47A-dnFRGR, or bG47A-PF4 (Fig   3) . All three viruses significantly inhibited the growth of M2 tumors compared to mock-treated (p < 0.01) and bG47A-dnFGFR was significantly better than bG47A-empty. This inhibition of tumor growth was reflected in increase survival (Fig 4) ,with an increased median survival from 22 days for PBS to 31 days for bG47A-dnFGFR.
2000
-.- groups and treated with PBS or 107 pfu bG47A-empty, bG47A-dnFGFR, and bG47A-PF4. Four intratumoral injections were given every 3 days. All vectors were significantly better at inhibiting tumor growth compared to PBS (* p < 0.01; student's t test) and dnFGFR and PF4 expressing G47A was significantly better than the control empty vector (* p < 0.05). Mice from the experiment in Figure 3 were followed until sacrifice (tumors > 2.1 cm 3 ).
Treatment with oncolytic HSV significantly increased survival compared to PBS (p < 0.01; logrank test) and bG47A-dnFGFR was significantly better than bG47A-empty (p < 0.05; log-rank test).
Anti-angiogenenic activity of dnFGFR and PF4 expressing G4 7A
So far we have been unable to detect sufficient numbers of immunostaining (anti-VWF or anti-CD31) vessels in the M2 tumors. To confirm that these vectors are actually inhibiting angiogenesis in vivo, we have used a human glioma cell line (U87), which is highly vascular (Fig   6, PBS) . Even G47A alone inhibited angiogenesis (Fig 5, 6 ), likely through replication in (106) were implanted in 6-8 week old nude mice. When tumors reached 50-100 mm 3 , the mice were randomized to 4 groups (N = 7 / group) and treated on days 0 and 3 with PBS or 5 x 105 pfu bG47A-empty, bG47A-dnFGFR, and bG47A-PF4. Tumors were harvested on day 7, snap-frozen, sectioned, and stained with anti-VWF (as described in Fig 5) . Microvessel counting was performed on 200X fields (0.724 mm 2 area). The mean vessel density (MVD) was the mean value of 5 individual, non-overlapping fields in the area of vascularization. Oncolytic HSV treated tumors had significantly fewer microvessels than PBS (p < 0.001) and bG47A-dnFGFR or bG47A-PF4 significantly less than bG47A-empty (p < 0.001).
proliferating endothelial cells (as seen in vitro in Fig 1) . Microvessel density after bG47A-dnFGFR or bG47A-PF4 treatment was only about 20% that seen in the mock (PBS) group and was significantly reduced compared to bG47A-empty (Fig 5) . Oncolytic herpes simplex viruses (HSV) have emerged as a promising platform for cancer therapy. Their large size permits insertion of therapeutic transgenes to augment the cytotoxicity of the backbone vector. Here we examine the activity of a dominant-negative FGF receptor (dnFGFR). Fibroblast growth factor (FGF) has been shown to stimulate the proliferation of Schwann cells in vitro, in addition to its mitogenic activity in endothelial cells, indicating its importance in malignant peripheral nerve sheath tumors (MPNST). We established MPNST cell lines transformed with dnFGFR or the control plasmid and showed that dnFGFR decreased cell proliferation and migration in vitro and reduced vascularity and delayed tumor growth in vivo.
APPENDIX
The dnFGFR transgene was inserted into oncolytic HSV G47 (deleted in 47/Usll promotor, 34.5, and a LacZ insertion inactivating ICP6), using the G47-BAC (bacterial artificial chromosome) system. G47-dnFGFR showed enhanced killing of both tumor and proliferating endothelial cells in vitro compared to the G47-empty control vector. In vivo, G47-dnFGFR was more efficacious than its non-expressing parent G47-empty at inhibiting MPNST growth. Therefore oncolytic HSV encoding antiangiogenic dominant-negative FGFR transgene is a new strategy for tumor treatment. Keywords: HSV Vectors; Cancer Gene Therapy; Targeted Gene Expression
